Ainos Corporation (AIMD) - Kewajiban jangka dawa marang modal

Ainos Corporation - logo grafis emiten AIMD

The long-term debt-to-equity ratio illustrates the debt obligations of Ainos, Inc. (AIMD), with 0.00 representing the latest level. The company is implementing AI systems for the instantaneous decoding of biological samples to minimize human error. Patents for rapid breath tests ensure business resilience, despite slow adoption. Operational efficiency is being enhanced through cloud IT outsourcing and the contract manufacturing of diagnostic systems.

Ainos - Utang jangka dawa marang modal AIMD (periode 28.04.2023 - 30.10.2026)
Sampel barang Ainos, Inc.

This ratio measures the proportion of long-term liabilities within the equity structure, determining financial stability during revenue contractions. For Ainos, Inc. (AIMD), this is critical, as the slow commercialization of AI diagnostics requires stable funding. By analyzing the long-term debt-to-equity ratio on GURU.Markets, an investor can see the balance between debt-driven growth and default risk. Low values confirm a conservative approach to capital, characterizing the company's assets as low-risk.

Perusahaan pesaing

Rasio utang jangka dawa marang ekuitas Agilent Technologies, Inc. (A)|Utang jangka dawa marang modal DGX|ILMN - Kewajiban jangka dawa marang modal|Utang jangka dawa marang modal EXAS (Exact Sciences)|RVTY: Rasio utang jangka dawa marang modal|Bio-Rad - Utang jangka dawa marang modal|NNNN - Utang jangka dawa marang modal|Sterigenics (SHC) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang modal QDEL|OPK (OPKO Health, Inc.) - Utang jangka dawa marang modal|Utang jangka dawa marang modal CareDx Corp|Utang jangka dawa marang ekuitas Maravai LifeSciences Holdings, Inc. (MRVI)|Utang jangka dawa marang ekuitas FLGT (Fulgent Genetics Inc)|Fluidigm - Rasio utang jangka dawa marang ekuitas|Cytek Corp (CTKB) - Kewajiban jangka dawa marang modal|OSUR - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal Exagen Inc. XGN|MDXH: Utang jangka dawa marang modal|LUCD - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Prenetics Global Limited|Insight Molecular (IMDX) - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang modal TRIB|Utang jangka dawa marang modal prophaselabs.com (PRPH)|Utang jangka dawa marang modal CODX (Co-Diagnostics)|Rasio tanggungan utang jangka dawa marang modal Heart Test Laboratories, Inc. (HSCS)|BMRA - Utang jangka dawa marang ekuitas|CDIO (Cardio Diagnostics) - Rasio utang jangka dawa marang modal|Virax Biolabs Group (VRAX) - Utang jangka dawa marang ekuitas|Kewajiban jangka dawa marang modal bluejaydx.com (BJDX)|Utang jangka dawa marang ekuitas Aspira Women's Health Inc.|Accelerate Diagnostics Inc. (AXDX) - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas CNTG (CENTOGENE, N.V.)|ENZ (enzo.com) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal FRES (Fresh2 Group)|Rasio tanggungan utang jangka dawa marang modal Genetic Technologies Ltd (GENE)|ME - Utang jangka dawa marang ekuitas|PMD (Psychemedics Corp.) - Rasio utang jangka dawa marang modal